{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:09:31Z","timestamp":1793045371068,"version":"4.5.0"},"reference-count":79,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Presidency of Turkey"},{"name":"Presidency of Strategy and Budget"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,23]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent hereditary kidney disease. Recent evidence suggests that the pathogenesis of ADPKD is a complex web of abnormal cellular processes including altered cell signaling, disordered cell metabolism, impaired autophagy, increased apoptosis, mitochondrial dysfunction and chronic inflammation. Sodium\u2013glucose cotransporter (SGLT) inhibitors (SGLTi) reduce body weight, blood pressure and blood glucose levels, have kidney and cardiovascular protective activity, and have been reported to decrease inflammation, increase autophagy and improve mitochondrial dysfunction. We now review results from preclinical studies on SGLTi for ADPKD identified through a systematic search of the MEDLINE, Cochrane Library, Embase and PubMed databases. Potential underlying mechanisms for the conflicting results reported as well as implications for clinical translation are discussed, as ADPKD patients were excluded from clinical trials exploring kidney protection by SGLT2 inhibitors (SGLT2i). However, they were not excluded from cardiovascular safety trials or trials for cardiovascular conditions. A post-hoc analysis of the kidney function trajectories and safety of SGLT2i in ADPKD patients enrolled in such trials may provide additional information. In conclusion, SGLT2i are cardio- and nephroprotective in diverse clinical situations. Currently, it is unclear whether ADPKD patients may benefit from SGLT2i in terms of kidney function preservation, and their safety in this population remains unexplored. We propose a roadmap to address this unmet clinical need.<\/jats:p>","DOI":"10.1093\/ckj\/sfac029","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T07:15:29Z","timestamp":1643267729000},"page":"1275-1283","source":"Crossref","is-referenced-by-count":35,"title":["Sodium\u2013glucose cotransporter inhibition in polycystic kidney disease: fact or fiction"],"prefix":"10.1093","volume":"15","author":[{"given":"Baris","family":"Afsar","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Suleyman Demirel University School of Medicine , Isparta, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rengin Elsurer","family":"Afsar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Suleyman Demirel University School of Medicine , Isparta, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5503-5305","authenticated-orcid":false,"given":"Atalay","family":"Demiray","sequence":"additional","affiliation":[{"name":"Department of Medicine, Koc University School of Medicine , Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevval","family":"Altay","sequence":"additional","affiliation":[{"name":"Department of Medicine, Koc University School of Medicine , Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Korkmaz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Suleyman Demirel University School of Medicine , Isparta, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmecit","family":"Yildiz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Uludag University School of Medicine , Bursa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Covic","sequence":"additional","affiliation":[{"name":"Nephrology Clinic, Dialysis and Renal Transplant Center, \u2018C.I. PARHON\u2019 University Hospital, and \u2018Grigore T. Popa\u2019 University of Medicine , Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9805-9523","authenticated-orcid":false,"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universidad Autonoma de Madrid and IIS-Fundacion Jimenez Diaz , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1297-0675","authenticated-orcid":false,"given":"Mehmet","family":"Kanbay","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Koc University School of Medicine , Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"key":"2022062300085802700_bib1","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ebiom.2019.08.041","article-title":"Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease","volume":"47","author":"Leonhard","year":"2019","journal-title":"EBioMedicine"},{"key":"2022062300085802700_bib2","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nrneph.2011.109","article-title":"Why kidneys fail in autosomal dominant polycystic kidney disease","volume":"7","author":"Grantham","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"2022062300085802700_bib3","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/ckj\/sfaa198","article-title":"SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia","volume":"13","author":"Fernandez-Fernandez","year":"2020","journal-title":"Clin Kidney J"},{"key":"2022062300085802700_bib4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","article-title":"Polycystic kidney disease","volume":"4","author":"Bergmann","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2022062300085802700_bib5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ndt\/gfv456","article-title":"Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice","volume":"31","author":"Gansevoort","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2022062300085802700_bib6","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"},{"key":"2022062300085802700_bib7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/MNH.0b013e3283621510","article-title":"Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease","volume":"22","author":"Devuyst","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2022062300085802700_bib8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in the treatment of polycystic kidney disease","volume":"25","author":"Torres","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2022062300085802700_bib9","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1523-1755.2004.00843.x","article-title":"Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells","volume":"66","author":"Belibi","year":"2004","journal-title":"Kidney Int"},{"key":"2022062300085802700_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/ki.2013.23","article-title":"The medicinal use of water in renal disease","volume":"84","author":"Wang","year":"2013","journal-title":"Kidney Int"},{"key":"2022062300085802700_bib11","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"key":"2022062300085802700_bib12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"key":"2022062300085802700_bib13","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"2022062300085802700_bib14","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"key":"2022062300085802700_bib15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/ndt\/gfu296","article-title":"An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease","volume":"30","author":"Ravichandran","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2022062300085802700_bib16","doi-asserted-by":"crossref","first-page":"F236","DOI":"10.1152\/ajprenal.00129.2010","article-title":"mTORC1\/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease","volume":"300","author":"Belibi","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022062300085802700_bib17","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","author":"Takiar","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022062300085802700_bib18","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000488807","article-title":"A randomized clinical trial of metformin to treat autosomal dominant polycystic kidney disease","volume":"47","author":"Seliger","year":"2018","journal-title":"Am J Nephrol"},{"key":"2022062300085802700_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cmet.2015.01.003","article-title":"Metformin action: concentrations matter","volume":"21","author":"He","year":"2015","journal-title":"Cell Metab"},{"key":"2022062300085802700_bib20","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cmet.2016.03.010","article-title":"Are metformin doses used in murine cancer models clinically relevant?","volume":"23","author":"Chandel","year":"2016","journal-title":"Cell Metab"},{"key":"2022062300085802700_bib21","doi-asserted-by":"crossref","first-page":"e1003053","DOI":"10.1371\/journal.pgen.1003053","article-title":"Network analysis of a Pkd1-mouse model of autosomal dominant polycystic kidney disease identifies HNF4\u03b1 as a disease modifier","volume":"8","author":"Menezes","year":"2012","journal-title":"PLoS Genet"},{"key":"2022062300085802700_bib22","doi-asserted-by":"crossref","first-page":"F122","DOI":"10.1152\/ajprenal.00352.2017","article-title":"PPAR\u03b1 agonist fenofibrate enhances fatty acid \u03b2-oxidation and attenuates polycystic kidney and liver disease in mice","volume":"314","author":"Lakhia","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022062300085802700_bib23","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2146\/ajhp120131","article-title":"Fenofibrate-associated nephrotoxicity: a review of current evidence","volume":"70","author":"Attridge","year":"2013","journal-title":"Am J Health Syst Pharm"},{"key":"2022062300085802700_bib24","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","article-title":"Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study","volume":"54","author":"Davis","year":"2011","journal-title":"Diabetologia"},{"key":"2022062300085802700_bib25","doi-asserted-by":"crossref","first-page":"e00337","DOI":"10.1128\/MCB.00337-17","article-title":"Mitochondrial abnormality facilitates cyst formation in autosomal dominant polycystic kidney disease","volume":"37","author":"Ishimoto","year":"2017","journal-title":"Mol Cell Biol"},{"key":"2022062300085802700_bib26","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nm.3092","article-title":"Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy","volume":"19","author":"Rowe","year":"2013","journal-title":"Nat Med"},{"key":"2022062300085802700_bib27","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.cmet.2019.09.012","article-title":"Ketosis ameliorates renal cyst growth in polycystic kidney disease","volume":"30","author":"Torres","year":"2019","journal-title":"Cell Metab"},{"key":"2022062300085802700_bib28","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"2022062300085802700_bib29","doi-asserted-by":"crossref","first-page":"F367","DOI":"10.1152\/ajprenal.00571.2013","article-title":"Mitochondrial dysfunction in the pathophysiology of renal diseases","volume":"306","author":"Che","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022062300085802700_bib30","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1002\/pmic.201100590","article-title":"Comparative proteomic analysis suggests that mitochondria are involved in autosomal recessive polycystic kidney disease","volume":"12","author":"Li","year":"2012","journal-title":"Proteomics"},{"key":"2022062300085802700_bib31","doi-asserted-by":"crossref","first-page":"830","DOI":"10.2353\/ajpath.2007.060455","article-title":"Involvement of hypoxia-inducible transcription factors in polycystic kidney disease","volume":"170","author":"Bernhardt","year":"2007","journal-title":"Am J Pathol"},{"key":"2022062300085802700_bib32","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1681\/ASN.2013030209","article-title":"Hypoxia-inducible factor-1\u03b1 causes renal cyst expansion through calcium-activated chloride secretion","volume":"25","author":"Buchholz","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2022062300085802700_bib33","doi-asserted-by":"crossref","first-page":"e0146654","DOI":"10.1371\/journal.pone.0146654","article-title":"Inhibition of aerobic glycolysis attenuates disease progression in polycystic kidney disease","volume":"11","author":"Riwanto","year":"2016","journal-title":"PLoS One"},{"key":"2022062300085802700_bib34","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1681\/ASN.2015030231","article-title":"2-deoxy-D-glucose ameliorates PKD progression","volume":"27","author":"Chiaravalli","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2022062300085802700_bib35","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.3390\/nu11071576","article-title":"Dietary care for ADPKD patients: current status and future directions","volume":"11","author":"Carriazo","year":"2019","journal-title":"Nutrients"},{"key":"2022062300085802700_bib36","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2215\/CJN.13291019","article-title":"Metabolic reprogramming in autosomal dominant polycystic kidney disease: evidence and therapeutic potential","volume":"15","author":"Nowak","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022062300085802700_bib37","article-title":"Ketogenic dietary interventions in autosomal dominant polycystic kidney disease\u2014a retrospective case series study: first insights into feasibility, safety and effects","author":"Sebastian Strubl","year":"2021","journal-title":"Clin Kidney J"},{"key":"2022062300085802700_bib38","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.mito.2021.02.016","article-title":"Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications","volume":"58","author":"Afsar","year":"2021","journal-title":"Mitochondrion"},{"key":"2022062300085802700_bib39","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1093\/ndt\/gfr744","article-title":"The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease","volume":"27","author":"Reed","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2022062300085802700_bib40","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1681\/ASN.2017070819","article-title":"Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease","volume":"29","author":"Nowak","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2022062300085802700_bib41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00109-015-1337-4","article-title":"Glucose promotes secretion-dependent renal cyst growth","volume":"94","author":"Kraus","year":"2016","journal-title":"J Mol Med (Berl)"},{"key":"2022062300085802700_bib42","doi-asserted-by":"crossref","first-page":"F79","DOI":"10.1152\/ajprenal.00652.2014","article-title":"Hyperglycemia in the absence of cilia accelerates cystogenesis and induces renal damage","volume":"309","author":"Sas","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022062300085802700_bib43","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.3390\/ijms21114113","article-title":"Epigenetic modifiers as potential therapeutic targets in diabetic kidney disease","volume":"21","author":"Martinez-Moreno","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2022062300085802700_bib44","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/nu11010042","article-title":"Effect of trehalose supplementation on autophagy and cystogenesis in a mouse model of polycystic kidney disease","volume":"11","author":"Chou","year":"2018","journal-title":"Nutrients"},{"key":"2022062300085802700_bib45","first-page":"158","article-title":"Autophagy activators suppress cystogenesis in an autosomal dominant polycystic kidney disease model","volume":"26","author":"Zhu","year":"2017","journal-title":"Hum Mol Genet"},{"key":"2022062300085802700_bib46","doi-asserted-by":"crossref","first-page":"F1235","DOI":"10.1152\/ajprenal.00348.2010","article-title":"Hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1) and autophagy in polycystic kidney disease (PKD)","volume":"300","author":"Belibi","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022062300085802700_bib47","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.34067\/KID.0007422020","article-title":"Examining the role of novel CKD therapies for the ADPKD patient","volume":"360","author":"Patel","year":"2021","journal-title":"Kidney"},{"key":"2022062300085802700_bib48","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1681\/ASN.2020111664","article-title":"Roxadustat for renal anemia in ESRD from PKD patients: is it safe enough?","volume":"32","author":"Liu","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2022062300085802700_bib49","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1053\/j.ajkd.2020.04.016","article-title":"Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics","volume":"77","author":"Packer","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2022062300085802700_bib50","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/ndt\/gfv422","article-title":"Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial","volume":"31","author":"Gansevoort","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2022062300085802700_bib51","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ndt\/gfx043","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial","volume":"33","author":"Torres","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2022062300085802700_bib52","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/ndt\/gfz137","article-title":"SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA","volume":"35","author":"Sarafidis","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2022062300085802700_bib53","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10157-020-02009-0","article-title":"Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease","volume":"25","author":"Horie","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"2022062300085802700_bib54","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1159\/000368540","article-title":"Inhibition of sodium\u2013glucose cotransporter 2 with dapagliflozin in han: SPRD rats with polycystic kidney disease","volume":"40","author":"Rodriguez","year":"2015","journal-title":"Kidney Blood Press Res"},{"key":"2022062300085802700_bib55","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/11318680-000000000-00000","article-title":"Sodium\u2013glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus","volume":"70","author":"Neumiller","year":"2010","journal-title":"Drugs"},{"key":"2022062300085802700_bib56","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cmet.2021.02.016","article-title":"A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors","volume":"33","author":"Sen","year":"2021","journal-title":"Cell Metab"},{"key":"2022062300085802700_bib57","doi-asserted-by":"crossref","first-page":"F1078","DOI":"10.1152\/ajprenal.00504.2009","article-title":"Polycystic kidney disease in Han:SPRD Cy rats is associated with elevated expression and mislocalization of SamCystin","volume":"299","author":"Nagao","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022062300085802700_bib58","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.199","article-title":"Targeting of sodium\u2013glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats","volume":"84","author":"Wang","year":"2013","journal-title":"Kidney Int"},{"key":"2022062300085802700_bib59","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.2337\/db13-0604","article-title":"Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans","volume":"62","author":"Abdul-Ghani","year":"2013","journal-title":"Diabetes"},{"key":"2022062300085802700_bib60","article-title":"PCK rat details","author":"Charles River"},{"key":"2022062300085802700_bib61","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1681\/ASN.2005060601","article-title":"Missense mutation in sterile alpha motif of novel protein SamCystin is associated with polycystic kidney disease in (cy\/+) rat","volume":"16","author":"Brown","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2022062300085802700_bib62","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/ng.2681","article-title":"ANKS6 is a central component of a nephronophthisis module linking NEK8 to INVS and NPHP3","volume":"45","author":"Hoff","year":"2013","journal-title":"Nat Genet"},{"key":"2022062300085802700_bib63","doi-asserted-by":"crossref","first-page":"e0125603","DOI":"10.1371\/journal.pone.0125603","article-title":"Effect of sodium\u2013glucose cotransport inhibition on polycystic kidney disease progression in PCK rats","volume":"10","author":"Kapoor","year":"2015","journal-title":"PLoS One"},{"key":"2022062300085802700_bib64","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/dmd.109.029165","article-title":"In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium\u2013glucose cotransporter type II inhibitor, in animals and humans","volume":"38","author":"Obermeier","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"2022062300085802700_bib65","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/jm701272q","article-title":"Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes","volume":"51","author":"Meng","year":"2008","journal-title":"J Med Chem"},{"key":"2022062300085802700_bib66","first-page":"585","article-title":"Pathophysiology of obstructive nephropathy in the newborn","volume":"18","author":"Chevalier","year":"1998","journal-title":"Semin Nephrol"},{"key":"2022062300085802700_bib67","doi-asserted-by":"crossref","first-page":"e14360","DOI":"10.14814\/phy2.14360","article-title":"Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume","volume":"8","author":"Masuda","year":"2020","journal-title":"Physiol Rep"},{"key":"2022062300085802700_bib68","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/ki.2012.225","article-title":"Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation","volume":"82","author":"Ho","year":"2012","journal-title":"Kidney Int"},{"key":"2022062300085802700_bib69","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.diabet.2019.11.006","article-title":"SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes","volume":"46","author":"Lytvyn","year":"2020","journal-title":"Diabetes Metab"},{"key":"2022062300085802700_bib70","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3389\/fphys.2019.00271","article-title":"Empagliflozin contributes to polyuria via regulation of sodium transporters and water channels in diabetic rat kidneys","volume":"10","author":"Chung","year":"2019","journal-title":"Front Physiol"},{"key":"2022062300085802700_bib71","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.2147\/DDDT.S114932","article-title":"Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date","volume":"11","author":"Cinti","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"2022062300085802700_bib72","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2022062300085802700_bib73","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/ckj\/sfy090","article-title":"The potential for improving cardio-renal outcomes by sodium\u2013glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study","volume":"11","author":"Herrington","year":"2018","journal-title":"Clin Kidney J"},{"key":"2022062300085802700_bib74"},{"key":"2022062300085802700_bib75","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1097\/HJH.0000000000002776","article-title":"Sodium\u2013glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun","volume":"39","author":"Sarafidis","year":"2021","journal-title":"J Hypertens"},{"key":"2022062300085802700_bib76","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s13063-019-3474-5","article-title":"Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)","volume":"20","author":"Jensen","year":"2019","journal-title":"Trials"},{"key":"2022062300085802700_bib77","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2022062300085802700_bib78","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S2213-8587(13)70050-0","article-title":"SGLT inhibitors in management of diabetes","volume":"1","author":"Tahrani","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022062300085802700_bib79","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/ckj\/sfaa232","article-title":"A randomized phase 1b cross-over study of the safety of low-dose pioglitazone for treatment of autosomal dominant polycystic kidney disease","volume":"14","author":"Blazer-Yost","year":"2021","journal-title":"Clin Kidney J"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfac029\/42600837\/sfac029.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/15\/7\/1275\/44142200\/sfac029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/15\/7\/1275\/44142200\/sfac029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T20:12:06Z","timestamp":1655928726000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/15\/7\/1275\/6517761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":79,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,1,31]]},"published-print":{"date-parts":[[2022,6,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfac029","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7]]},"published":{"date-parts":[[2022,1,31]]}}}